---
title: "CYWC628 — Stuff That Spins"
description: "Narrative intelligence for CYWC628: 1 tracked articles, claims, and spin patterns across AI and technology coverage."
	canonical: "https://stuffthatspins.com/entities/cywc628"
html: "https://stuffthatspins.com/entities/cywc628"
json: "https://stuffthatspins.com/entities/cywc628.json"
markdown: "https://stuffthatspins.com/entities/cywc628.md"
keywords: ["CYWC628", "product", "AI", "technology", "spin analysis"]
json_ld: |
  {"@context":"https://schema.org","@graph":[{"@type":"Product","@id":"https://stuffthatspins.com/entities/cywc628","name":"CYWC628","description":"Narrative intelligence for CYWC628 across AI and technology coverage.","url":"https://stuffthatspins.com/entities/cywc628","identifier":"cywc628"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Stuff That Spins","item":"https://stuffthatspins.com/"},{"@type":"ListItem","position":2,"name":"CYWC628","item":"https://stuffthatspins.com/entities/cywc628"}]},{"@type":"ItemList","name":"Articles about CYWC628","itemListElement":[{"@type":"ListItem","position":1,"url":"https://stuffthatspins.com/spin/fibrobiologics-reports-second-quarter-2026-financial-results-progresses-clinical-trial-evaluating-lead-wound-care-candid","name":"FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate"}]},{"@type":"ItemList","name":"Claims involving CYWC628","itemListElement":[{"@type":"ListItem","position":1,"item":{"@type":"Claim","text":"First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers"}}]}]}
---

# CYWC628

**Type:** product  
## Related Articles

- [FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate](https://stuffthatspins.com/spin/fibrobiologics-reports-second-quarter-2026-financial-results-progresses-clinical-trial-evaluating-lead-wound-care-candid) — July 31, 2026

## Related Claims

- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers

---
*HTML version: https://stuffthatspins.com/entities/cywc628*